Evidence map›Paper›PMID 34170524›Full record

ArticleBiotechnology and bioengineering2021

Technology transfer of a monitoring system to predict product concentration and purity of biopharmaceuticals in real-time during chromatographic separation.

Anna Christler, Theresa Scharl, Dominik G Sauer, Johannes Köppl, Anne Tscheließnig, Cabir Toy, Michael Melcher, Alois Jungbauer, Astrid Dürauer

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna ChristlerAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.
Theresa ScharlAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.
Dominik G SauerAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.
Johannes KöpplTechnical Operations Large Molecules, Manufacturing Science & Technologies, Novartis, Kundl, Austria.
Anne TscheließnigBoehringer Ingelheim Regional Center Vienna GmbH & Co KG, Vienna, Austria.
Cabir ToyBoehringer Ingelheim Regional Center Vienna GmbH & Co KG, Vienna, Austria.
Michael MelcherAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.
Alois JungbauerAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.ORCID 0000-0001-8182-7728
Astrid DürauerAustrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.ORCID 0000-0002-6007-7697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Technological developments require the transfer to their location of application to make use of them. We describe the transfer of a real-time monitoring system for lab-scale preparative chromatography to two new sites where it will be used and developed further. Equivalent equipment was used. The capture of a biopharmaceutical model protein, human fibroblast growth factor 2 (FGF-2) was used to evaluate the system transfer. Predictive models for five quality attributes based on partial least squares regression were transferred. Six out of seven online sensors (UV/VIS, pH, conductivity, IR, RI, and MALS) showed comparable signals between the sites while one sensor (fluorescence) showed different signal profiles. A direct transfer of the models for real-time monitoring was not possible, mainly due to differences in sensor signals. Adaptation of the models was necessary. Then, among five prediction models, the prediction errors of the test run at the new sites were on average twice as high as at the training site (model-wise 0.9-5.7 times). Additionally, new prediction models for different products were trained at each new site. These allowed monitoring the critical quality attributes of two new biopharmaceutical products during their purification processes with mean relative deviations between 1% and 33%.

Indexed as

Biological ProductsFibroblast Growth Factor 2ChromatographyHumansRecombinant ProteinsBiological ProductsFibroblast Growth Factor 2Recombinant Proteinscritical quality attributesmodelingonline monitoringPLSpredictionsoft sensor

Identifiers

PMID34170524
PMCPMC8518415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.